Distribuzione geografica
Continente #
NA - Nord America 2014
EU - Europa 440
AS - Asia 100
AF - Africa 70
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 2643
Nazione #
US - Stati Uniti d'America 1976
IT - Italia 91
FI - Finlandia 89
NG - Nigeria 64
NL - Olanda 44
SE - Svezia 39
CA - Canada 37
FR - Francia 37
DE - Germania 34
GB - Regno Unito 27
BE - Belgio 25
IE - Irlanda 22
CN - Cina 19
JP - Giappone 13
IN - India 12
SG - Singapore 12
TR - Turchia 12
HK - Hong Kong 11
CL - Cile 7
EG - Egitto 6
IR - Iran 6
AT - Austria 5
EU - Europa 5
IL - Israele 5
PT - Portogallo 4
RU - Federazione Russa 4
AU - Australia 3
BD - Bangladesh 3
CZ - Repubblica Ceca 3
KR - Corea 3
UA - Ucraina 3
A2 - ???statistics.table.value.countryCode.A2??? 2
ES - Italia 2
ID - Indonesia 2
NO - Norvegia 2
PL - Polonia 2
BR - Brasile 1
CH - Svizzera 1
DK - Danimarca 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
MD - Moldavia 1
MM - Myanmar 1
MX - Messico 1
PE - Perù 1
PH - Filippine 1
RO - Romania 1
Totale 2643
Città #
Chandler 517
Wilmington 409
San Mateo 162
Ann Arbor 131
Helsinki 89
Lawrence 83
Princeton 83
Leawood 77
Benin City 64
Amsterdam 41
Milan 38
Paris 36
Woodbridge 30
Boardman 25
Brussels 23
Dublin 22
Fairfield 22
London 17
Toronto 17
San Diego 14
Kocaeli 9
Abbiategrasso 8
Andover 7
Montreal 7
Norwalk 7
Singapore 7
Monmouth Junction 6
Redwood City 6
Seattle 6
Cairo 5
Redmond 5
Umeda 5
Falls Church 4
Los Angeles 4
Porto 4
Shanghai 4
Shenzhen 4
Tai Kok Tsui 4
Winnipeg 4
Ashburn 3
Hanover 3
Raleigh 3
Sacramento 3
Verona 3
Ariano nel Polesine 2
Carrara 2
Chicago 2
Clearwater 2
Dhaka 2
Jakarta 2
Lambeth 2
Minatomirai 2
Montréal 2
Moscow 2
Munich 2
Okayama 2
Phoenix 2
Prague 2
Rome 2
Sherbrooke 2
Vienna 2
Warsaw 2
Ankara 1
Bengaluru 1
Brighton 1
Bucharest 1
Budapest 1
Caderzone 1
Cambridge 1
Central 1
Central District 1
Changchun 1
Chisinau 1
Chittagong 1
Chula Vista 1
Concord 1
Copenhagen 1
Croydon 1
Daly City 1
Des Moines 1
Douglas 1
Eden Prairie 1
Edogawa 1
Egham 1
Erzincan 1
Falkenstein 1
Florence 1
Fort Lauderdale 1
Frankfurt am Main 1
Frederick 1
Gelsenkirchen 1
Guelph 1
Gurgaon 1
Hayward 1
Hebei 1
Henderson 1
Hyderabad 1
Incheon 1
Istanbul 1
Jilove u Prahy 1
Totale 2095
Nome #
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 97
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 63
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 60
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 45
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 45
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 45
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 45
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 44
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 44
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 44
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 43
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 43
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 43
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 42
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 42
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 42
Cabozantinib for the treatment of hepatocellular carcinoma 41
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 41
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 41
Biomarkers in Hepatocellular Carcinoma-Letter 40
Reply to Y. Pointreau et al 40
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 39
COVID-19 and liver cancer clinical trials: not everything is lost 38
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 38
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 38
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 38
Shaping the landscape of immune oncology in hepatocellular carcinoma 37
Role of liver biopsy in hepatocellular carcinoma 37
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 37
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 36
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 36
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 36
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 35
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 35
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 35
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 35
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 35
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 34
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 34
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 34
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 34
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 34
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 34
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. 33
Tivantinib for hepatocellular carcinoma 32
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 32
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 32
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 32
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 31
Regorafenib for the treatment of unresectable hepatocellular carcinoma 31
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. 31
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 29
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 29
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 29
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 27
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 26
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 25
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma 25
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 24
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 24
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 24
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 24
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 24
Tumour burden score and immune???related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors 22
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 22
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges 22
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 22
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 21
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade 20
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma 20
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 20
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 19
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 19
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 19
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 16
OncoAlert Round Table Discussions: The Global COVID-19 Experience. 15
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 14
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 12
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 12
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 11
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 11
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 11
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 11
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. 9
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 9
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 9
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 7
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 7
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 6
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 5
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 2
Response prediction to EGFR-targeted therapies in colorectal cancer 2
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy 2
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer 2
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells 2
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 2
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 2
Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib : does intratumoral heterogeneity matter? 2
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 2
Totale 2773
Categoria #
all - tutte 14612
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14612

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0000 00 00 0036
2020/2021760 3564 23230 11846 134951086
2021/2022553 1582105 1614 2480 641048239
2022/20231459 19681137188 147119 15114 2351071200
Totale 2781